Valuation: Alzinova AB

Market Cap 22Cr 2.24Cr 1.96Cr 1.81Cr 1.68Cr 3.18Cr 212.92Cr 3.23Cr 8.44Cr 105.08Cr 8.42Cr 8.24Cr 363.2Cr P/E 2026 *
-5.19x
P/E 2027 * -3.68x
Enterprise Value 20Cr 2.08Cr 1.82Cr 1.68Cr 1.55Cr 2.95Cr 197.21Cr 3Cr 7.81Cr 97Cr 7.8Cr 7.63Cr 336.41Cr EV / Sales 2026 *
6.41x
EV / Sales 2027 * -
Free-Float
82.23%
Yield 2026 *
-
Yield 2027 * -
1 day+191.67%
1 week+182.26%
Current month+182.26%
1 month+204.35%
3 months+135.29%
6 months+69.70%
Current year+68.88%
1 week 0.48
Extreme 0.48
1.45
1 month 0.44
Extreme 0.438
1.45
Current year 0.38
Extreme 0.382
1.45
1 year 0.38
Extreme 0.382
2.28
3 years 0.38
Extreme 0.382
4.62
5 years 0.38
Extreme 0.382
8.81
10 years 0.38
Extreme 0.382
44.9
Manager TitleAgeSince
Chief Executive Officer 59 01/10/2024
Chief Operating Officer 54 17/08/2011
Director of Finance/CFO 57 27/03/2024
Director TitleAgeSince
Director/Board Member 61 01/09/2015
Director/Board Member 69 01/01/2018
Director/Board Member - 01/01/2018
Change 5-day change 1-year change 3-year change Capi.($)
+191.67%+182.26%-17.55%-56.18% 77.03L
-1.03%+5.24%+2.94%+9.41% 5.03TCr
+0.25%+1.70%+419.39%+621.71% 4.04TCr
-0.16%+8.42%+28.20%+63.00% 3.44TCr
+1.10%+7.77%+28.18%-3.96% 3.44TCr
+1.31%-0.56%+5.12%+33.90% 2.63TCr
-0.35%+0.09% - - 1.66TCr
-3.33%+3.15%+71.30%+131.94% 1.61TCr
+3.79%+8.88%+106.63%+106.63% 1.37TCr
+0.32%+0.53%+14.33%+21.47% 1.37TCr
Average +19.36%+22.02%+73.17%+103.10% 2.46TCr
Weighted average by Cap. +0.10%+4.58%+95.81%+141.26%

Financials

2026 *2027 *
Net sales 3.14Cr 32.42L 28.37L 26.14L 24.23L 46L 31Cr 46.74L 1.22Cr 15Cr 1.22Cr 1.19Cr 52Cr -
Net income -32L -3L -3L -3L -2L -5L -3.14Cr -5L -12.44L -1.55Cr -12.42L -12.15L -5.36Cr -5.04Cr -52.07L -45.56L -41.99L -38.92L -73.88L -49Cr -75.07L -1.96Cr -24Cr -1.95Cr -1.91Cr -84Cr
Net Debt -1.6Cr -16.55L -14.48L -13.34L -12.37L -23.48L -16Cr -23.86L -62.22L -7.75Cr -62.12L -60.77L -27Cr -1.9Cr -19.65L -17.19L -15.85L -14.69L -27.88L -19Cr -28.33L -73.89L -9.2Cr -73.76L -72.16L -32Cr
Logo Alzinova AB
Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimer’s disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric Aβ that damages brain synapses.
Employees
7
Date Price Change Volume
07/26/07 SEK 1.400 +191.67% 9,70,09,916
06/26/06 SEK 0.4800 -3.03% 10,43,697
03/26/03 SEK 0.4950 -4.81% 10,57,323
02/26/02 SEK 0.5200 -1.52% 18,08,347
01/26/01 SEK 0.5280 +6.45% 42,11,288

Annual profits - Rate of surprise